Insight Conference
Rayyan Zafar, BSc. MSc.
Vincent Verroust PhD
6:05pm - 7:05pm


Psilocybin in the Treatment of Anorexia Nervosa: the English Transition of a French 1959 Case Study

Authors: Vincent Verrousta, b,, Rayyan ZafarMeg J. Spriggsc

a Centre Alexandre-Koyré, Campus Condorcet, 2 cours des humanités, 93322 Aubervilliers Cedex, France

Institut des humanités en médecine du Centre hospitalier universitaire vaudois, avenue de Provence 82, 1007 Lausanne, Suisse

c Centre for Psychedelic Research, Division of Brain Sciences, Imperial College London, Commonwealth Building, Hammersmith Campus, Londres, W12 0NN, Angleterre

Psilocybin is a psychotropic molecule that is a partial agonist of serotonin 2A receptors and is the main psychoactive compound in hallucinogenic mushrooms. After the observation in 1953 in Mexico of ritual practices involving ingestion of such mushrooms, psilocybin was chemically characterised and synthesised in 1958 thanks to the collaboration between the Muséum national d’Histoire naturelle in France and the Sandoz pharmaceutical laboratories in Switzerland. The interest of this substance in psychiatric therapy was then evaluated for the first time at the Sainte-Anne Hospital in Paris, by the team of Professor Jean Delay. Among the patients who received this substance was a a 35-year-old woman who was hospitalised for compulsive manifestations emblematic of anorexia nervosa and who experienced an immediate and lasting improvement. The original 1959 article (published in the Annales de la Société médico-psychologique) gives details of the patient’s family background, biography and clinical examination. It then outlines the observations after two injections of psilocybin four days apart, in particular the autobiographical verbal statements that allowed the patient to understand the psychogenesis of her illness.  After a long hiatus, psilocybin is once again the subject of medical research, with clinical trials now underway assessing psilocybin in the treatment of anorexia nervosa (NCT04505189; NCT04052568; NCT04661514) and this 1959 case study, is the first known demonstration of the safety and efficacy of psilocybin treatment of anorexia nervosa. This case study thus provides an interesting insight into possible therapeutic mechanisms and is of great interest to the field moving forward.


Phd Candidate

Rayyan Zafar, BSc. MSc.

Department of Brain Sciences, Imperial College London
View Speaker Profile
PhD candidate

Vincent Verroust PhD

Paris Institut des humanités en médecine, Centre hospitalier universitaire vaudois, Lausanne
View Speaker Profile